Core Viewpoint - The article highlights the successful development and approval of the TMS100 system by Zhipu Medical Technology, marking a significant advancement in China's medical device industry, particularly in precise temperature management for critical medical scenarios [1][2]. Company Summary - Zhipu Medical Technology has developed the TMS100 system, which is the first domestic precision temperature control treatment device approved for market use in China [1]. - The TMS100 system utilizes innovative multi-modal adaptive temperature control algorithms and an intelligent risk warning platform, achieving a temperature control precision of ±0.1°C, which meets international standards [1]. - The company aims to provide more efficient and precise treatment tools for clinicians while reducing medical costs and benefiting more patients [2]. Industry Summary - Chengdu Tianfu International Bio-city is focusing on high-quality development in the medical device industry, targeting segments such as in vitro diagnostics, interventional products, medical materials, and life support devices [2]. - The bio-city has attracted major companies like GE Healthcare and MaiKe Bio, fostering the development of significant medical devices that fill gaps in both domestic and international markets [2]. - Future plans for Chengdu Tianfu International Bio-city include promoting the integration of production and research in the medical device industry and accelerating the transformation of scientific achievements [2].